Archive for the ‘Treatment’ Category

Parvovirus B-19 or Fifth Disease & Lyme

https://sites.google.com/site/virginialyme/tick-borne-diseases/parvovirus-b19

Parvovirus B19

Parvovirus B19- Opportunistic, Chronic or Tick Borne?

Parvoviruses are some of the smallest viruses found in nature. Patients with chronic Lyme disease may test positive for parvovirus B19. Studies are needed to determine if parvovirus is reactivated after a Lyme infection in some people, if it is passed along by ticks with Lyme bacteria and many other known coinfections or if it is a chronic illness that can surface when the immune system is busy fighting new infections.

What is parvovirus B19 (aka “fifth disease or slapped-cheek syndrome)?”

Parvo B-19 is an illness that occurs most commonly in children. The child may have a “slapped-cheek” rash on the face and/or a lacy red rash on the trunk and limbs. Occasionally, the rash may itch. The child may have a fever, malaise, or a “cold” a few days before the rash breaks out. The rash may disappear on its own, with no treatment.

What causes parvovirus B19?

This particular virus (B19) infects humans. Pet dogs or cats may be immunized against “parvovirus,” but these are animal parvoviruses that are not known to infect humans. Therefore, a child cannot “catch” parvovirus from a pet dog or cat, and a pet cat or dog cannot catch human parvovirus B19 from an ill child.  (See link for article)

_________________

**Comment**

Great reminder that COVID is not the only enemy out there.

A few points:

  • Adults can get B19 as well.
  • Patients with B19, as with any other virus, can also be asymptomatic (don’t have symptoms). About 20% don’t develop symptoms at all.
  • Besides the tell-tale facial rash, joint pain/swelling is also common.  Joints most affected are hands, wrists, and knees. Pain may resolve quickly or last months or even years.
  • B19 is contagious before the rash appears. It has been found in respiratory secretions and the patient appears to “just have a cold.”
  • Like most viruses, it takes 3-14 days to become infected and lasts up to 3 weeks.
  • Similarly to the EM rash being diagnostic for Lyme, the rash for B19 is also diagnostic. A blood test may be done to look for antibodies.
  • While B19 is typically mild, it can cause serious illness in those with sickle-cell or anemia (the rash rarely appears with these cases). Also, those with cancers, immune deficiencies, beneficiaries of organs, or who have HIV are also at risk for more severe illness.
  • While the article states that the only treatment is palliative care (aspirin, anti-itch medication, fluids, rest, etc.) there is also blood ozone, IV supplements, immune globulin, and anti-virals.

The article brings up a very important point: do ticks and other insects transmit these viruses (they are known to transmit many other viruses) directly or do they reactivate latent viruses within the body or both?  My wager is that both occur.

Lyme/MSIDS have been struggling with viruses due to tick-borne illness for decades. Here’s a list:

  • EBV(epstein-barr virus)
  • herpes
  • powassan
  • bourbon virus
  • deer-tick virus
  • heartland virus
  • Colorado tick fever
  • tick-borne encephalitis
  • Crimean-Congo hemorrhagic fever
  • Severe fever with thrombocytopenia syndrome (caused by SFTS virus)

The best treatment is to treat the underlying tick-borne infections and strengthen the immune system with adjunctive therapies that support the body. Also, many find anti-viral agents very helpful.

For more:

Category:

Lyme, Treatment, Viruses

Ivermectin Trial on Hold Citing ‘Supply Issues’ & Judge Holds Hospital in Contempt of Court: The Ivermectin Saga Continues

The ivermectin arm of the U.K’s PRINCIPLE trial is “currently paused due to supply issues,” according to the trial’s website. Guess who manufacturers ivermectin? Merck – the company that was accused of fraud, deceit, negligence, falsifying data, paid $4.85 billion settlement with injured plaintiffs over Vioxx when it did not disclose known heart attack risk in its clinical trial data, and who is in bed with our government, paying it royalties.

Here’s what you need to know:

  • The cost of a complete five-day course of Molnupiravir is $700 — or $70 per pill. That amounts to a 4,000% markup over what it costs Merck to make the drug.
  • Citing 2013 prices provided by the WHO, Campbell said a five-day course of ivermectin — 10 3mg pills — costs $0.53. (However, at today’s U.S. prices, 10 3mg pills cost about $39).

The company said that it has “concluded that the probability of ivermectin providing a potentially safe and efficacious treatment option for SARS-CoV-2 infection is low and have prioritized internal efforts towards the development of alternate candidates that provide a higher probability of success for the treatment of COVID-19.”

Ha, ha, ha….seriously, this is laughable if it wasn’t killing people.

OK, so you know ivermectin works and you are basically taking your marbles and going home to create your own game, a patented drug which will make you a whole lot more money. I get it, out with the old in with the new.

__________________

https://www.theblaze.com/news/judge-holds-hospital-in-contempt-of-court-for-refusing-ivermectin-covid-patient

Judge holds hospital in contempt of court for refusing ivermectin to COVID patient on ventilator, ignoring court order

Chris Enloe

December 14, 2021

A Virginia hospital was held in contempt of court Monday after refusing to administer ivermectin to a woman who has been battling COVID-19 since early October.

What are the details?

Kathleen Davies, a 63-year-old northern Virginia woman, became severely ill with COVID in October, and she has been on a ventilator since Nov. 3.

Davies was prescribed ivermectin by her family doctor, but she could not complete her regimen upon being admitted to the Fauquier Hospital in Warrenton. That’s because the northern Virginia hospital refused to administer the drug, “citing medical, legal and practical concerns,” the Fauquier Times reported.  (See link for article)

________________

**Comment**

A family member who works at the hospital urged the hospital to give her ivermectin to no avail. Then in Dec. they took legal action and a circuit court judge ordered the hospital to give her the drug.  The hospital ignored the order.

The hospital is relying on “consensus” medicine and the fact the patient’s doctor does not have hospital privileges.

The judge then ruled that this is not state law and again ordered the hospital to permit giving ivermectin.

Hospital: “Talk to the butt.”

The judge finally held the hospital in contempt of court for “needlessly interposing requirements that stand in the way of the patient’s desired physician administering investigational drugs as part of the Health Care Decisions Act and the federal and state Right to Try Acts.” and imposed daily $10,000 fines retroactive to Dec. 9, 2021.

The judge gave the hospital until 9 p.m. on Monday to administer ivermectin, or he would levy additional fines.

Kathleen Davies was given ivermectin at 8:45 p.m.

And that is what it takes to save lives in the crazy, topsy-turvy world of COVID where experimental, fast-tracked, never approved for human use injections, that don’t stop transmission or infection, are ineffective, and which have caused more adverse reactions and death than any other “vaccine” in 30 years are accepted without hesitation and proven, cheap, effective drugs with decades of safety behind them are denied to dying patients. Please also read this important article on how hospitals get money for utilizing “consensus based” medicine even when it doesn’t work and costs lives.

The hospital payments include:

  • A “free” required PCR test in the Emergency Room or upon admission for every patient, with government-paid fee to hospital.
  • Added bonus payment for each positive COVID-19 diagnosis.
  • Another bonus for a COVID-19 admission to the hospital.
  • A 20 percent “boost” bonus payment from Medicare on the entire hospital bill for use of remdesivir instead of medicines such as Ivermectin.
  • Another and larger bonus payment to the hospital if a COVID-19 patient is mechanically ventilated.
  • More money to the hospital if cause of death is listed as COVID-19, even if patient did not die directly of COVID-19.
  • A COVID-19 diagnosis also provides extra payments to coroners.

Please see this article where ivermectin saved more patients from the jaws of death.

“Consensus based” medicine starts at the top with corrupt public health agencies, but 12,700 doctors and scientists have signed the Rome Declaration and have endorsed ivermectin as a COVID treatment.

An internist ultimately administered a five-day course of 24 milligrams of ivermectin, from November 8 through November 12.  The doctor stated: “Every day after ivermectin, there was accelerated and stable improvement,” said Dr. Bain, who administered the drug in two previous court cases after hospitals refused. “Three times we’ve shown something,” he told me. “There’s a signal of benefit for ventilator patients.”

  • With only a 10-20% chance of survival, the judge listed ivermectin’s possible side-effects from a government website: dizziness, pruitus, nausea/diarrhea, and stated that effects were so minimal that the patient’s condition outweighs risks by 100-fold.
  • A Kool-aid drinking doctor had the audacity to state that the risk of ivermectin gives no benefits.
  • This patient’s case is the costliest with three decisions, four court appearances, and now an appeal that is certainly moot. The attorney battled another case in the same health system that involved Nurije Fype, age sixty-eight. Her case inspired Dr. Ng to file suit. Fype, who is probably only alive today due to judicious treatment with ivermectin, is now four and a half months downstream and doing great.
  • Sun Ng, a 71-year-old man who spent 22 days on a ventilator with COVID-19, was discharged following a court-mandated successful treatment cycle of ivermectin.  Source

In other words, Ng made a FULL RECOVERY – and so did 80-year-old Judith Smentkiewicz, also on a ventilator with a 20% chance of survival. 

Also read this doctor’s experience with 0/2000 hospitalizations utilizing early treatment which includes ivermectin.  Here’s another doctor’s experience saving 1,700 utilizing HCQ, zinc, and azithromycin.

How many more cases must be presented before doctors smell a rat? 

Answer: cases don’t matter. 

All that matters is “consensus based” medicine (think Communism) where corrupt public health ‘authorities’ proclaim science, and Dr. Evil has been at it a long time.

And speaking of Communism, COVID investigator funded by Chinese Communist Party just removed from WHO team, is now calling on ‘Justice’ for online threats, and Dr. Evil, the doctor who has no qualms funding research that forced children to ingest harmful and dangerous chemotherapy drugs, on abominable experiments on dogs, and torturing monkeys, putting fetal scalps on rats, and taking American tax-dollars to fund illegal ‘gain of function’ research to make coronaviruses more virulent in humans is calling for his comrade’s protection. He also sees no problem with conflicts of interest.

 

Summary:

  • Koopmans was listed as one of 28 members on WHO’s Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)
  • SAGO’s updated member list fails to include Koopmans as a contributor to the effort to allegedly uncover the origins of COVID-19
  • The National Pulse unearthed her role on a scientific advisory board of the Centers for Disease Control of Guangdong China
  • She has also authored scientific research papers and journal articles supported by Chinese Communist Party grants

 

Category:

Treatment, vaccines, Viruses

FDA Panel Just Barely Recommends Molnipiravir. Data Show Birth Defects in Rats

https://popularrationalism.substack.com/p/fda-panel-just-barely-recommends

FDA Panel Just Barely Recommends Molnupiravir. Data Show Birth Defects in Rats

Health advisors vote 13 for and 10 against Molnupirivir for COVID-19 Patients. Issues with lack of evidence of efficacy against new variants and birth defects cause doubt.

The FDA may or may not take the weak recommendation by a health advisory committee. With 43% of the health advisors voting against recommendation, and the data on Molnupiravir lacking, the US awaits the decision by FDA on its recommendation position on Merck’s alleged “wonder drug”.

I had written early on the extraordinary hypocrisy of Molnupiravir, given that the press had advanced a press-release (not a peer-reviewed study) on the efficacy and safety of the drug. Even now, the peer-reviewed literature only includes studies with less than 20 patients for first-in-human and dose variation study.

Merck had decided to do an “interim analysis” of an ongoing clinical trial, and yet compared to the very strong evidence in support of Ivermectin in the reduction of hospitalization and risk of death (See https://ivmmeta.com).

So what made the 10 health advisors skeptical?

For one, data from studies in pregnant rats showed birth defects.

From CBS News:

“Given the large potential population affected, the risk of widespread effects on potential birth defects has not been adequately studied,” said Dr. Sankar Swaminathan of the University of Utah School of Medicine, who voted against the drug.”

With another example of hypocrisy, one panelist said that if the FDA restricts the use of molnupiravir in pregnant women, they would be denying women choice.

“I don’t think you can ethically tell a woman with COVID-19 that she can’t have the drug if she’s decided that’s what she needs,” said Cragan, a panel member and staffer with the Centers for Disease Control and Prevention. “I think the final decision has to come down to the individual woman and her provider.”

Read that again.

When FDA panelists start considering the level of evidence available for their favorites pharma partners, and start arguing for informed consent and health freedom when it comes to vaccines, we can start taking them seriously.

Until then, they are just going through the motions and abusing the public trust and they, and the FDA’s decisions, do not deserve our respect or attention.

_________________

**Comment**

And yet, that same woman, or man, or even a medical doctor can not “decide” that they need ivermectin or HCQ because, well – that’s just bad and regulatory groups will pounce upon you.  Hypocrisy indeed.

Read this article on a comparison between Molnupiravir and ivermectin.

  • The cost of a complete five-day course of Molnupiravir is $700 — or $70 per pill. That amounts to a 4,000% markup over what it costs Merck to make the drug.
  • Citing 2013 prices provided by the WHO, Campbell said a five-day course of ivermectin — 10 3mg pills — costs $0.53. (However, at today’s U.S. prices, 10 3mg pills cost about $39).

India and Argentina no longer fear COVID, they simply treat it.  Sub-Saharan Africa is void of COVID due to widespread river blindness which was brought under control by insecticides and by large-scale distribution of ivermectin since 1989.

But, the only drug offered U.S. patients is the expensive, worthless drug remdesivir which caused more than 500 deaths in the first year of usage.  There have been 20 deaths in 19 years of ivermectin usage.  Source

  • The FDA, spurred by “multiple” reports of ivermectin ‘poisoning,’ lied when it put out a post on it causing “serious harm, seizures, coma, and even death”. When the author inquired on how many is “multiple,” she was told FOUR.  Yet, the FDA had no trouble approving remdesivir which has caused far more deaths.
But now, they are offering another expensive, worthless drug.

Category:

Activism, Treatment, vaccines

Lyme Disease in an African American Child With Down’s Syndrome

https://danielcameronmd.com/lyme-disease-in-an-african-american-child-with-downs-syndrome/

Lyme disease in an African American child with Down’s syndrome

Welcome to another Inside Lyme Podcast with your host Dr. Daniel Cameron. In this episode, Dr. Cameron discusses the case of a 3-year-old African American child with Down’s syndrome, developmental delays and disseminated Lyme disease.

By

“A case of disseminated Lyme disease in a child with skin of color” was published by Bax and colleagues in the journal Pediatric Dermatology.¹ The child, who had trisomy 21 (Down’s syndrome) and developmental delays, had a history of playing outside in an area where ticks were observed.

According to the authors, the young girl had experienced a high fever for 9 days and had a 5-day history of rashes. The rashes were asymptomatic and would wax and wane. They consisted of “scattered ill-defined 2-5 cm erythematous patches on the back, abdomen, and upper and lower extremities,” a pattern consistent with disseminated Lyme disease.

There were other manifestations of Lyme disease, as well. “While the patient could not verbalize pain, her mother noted that she was walking less and was not tolerating her leg braces or shoes,”  wrote the authors. “She also appeared increasingly fatigued and agitated.”

The doctors ruled out COVID-19, inflammatory syndrome (MIS-C), and Incomplete Kawasaki’s syndrome.  “Incomplete Kawasaki’s syndrome was also considered given her hand/foot erythema, skin lesions, fingertip desquamation, and elevated CRP.”

Laboratory tests supported the diagnosis of Lyme disease. The child showed “significant improvement” with 14 days of amoxicillin.

Challenges raised by this case

The authors addressed the challenges in diagnosing Lyme disease in people of color, citing a study by Fix and colleagues.2

“African Americans in Borrelia burgdorferi-endemic regions have been reported to have higher rates of extracutaneous sequelae, such as arthritis, and lower rates of erythema migrans compared with Caucasians, suggesting that the characteristic rash in skin of color may go unrecognized until more severe symptoms manifest,” the authors wrote.

They did not address the challenges in diagnosing Lyme disease in people with Down’s syndrome and development delays. Fortunately, the 3-year-old toddler presented with a disseminate Lyme disease rash, symptoms, and functional problems, which led to an accurate diagnosis. This would have undoubtedly been more difficult without these findings. 

Treatment 

The authors did not discuss long-term outcomes or treatment concerns. In some cases, Lyme disease patients may have a co-infection which would require different types of treatment. For instance, amoxicillin would not be effective in treating Anaplasmosis and Babesia.

The following questions are addressed in this Podcast episode:

  1. Have you treated children with Down’s syndrome and developmental delays for Lyme disease?
  2. What were the diagnostic and treatment challenges in working with this child?
  3. Have you also treated children and adults of color? If so, what diagnostic and treatment challenges do they pose?
  4. Tell me about your experience with Lyme disease in children on the autism spectrum.

Thanks for listening to another Inside Lyme Podcast. Please remember that the advice given is general and not intended as specific advice to any particular patient. If you require specific advice, please seek that advice from an experienced professional.

Inside Lyme Podcast Series

This Inside Lyme case series will be discussed on my Facebook page and made available on podcast and YouTube.  As always, it is your likes, comments, and shares that help spread the word about this series and our work. If you can, please leave a review on iTunes or wherever else you get your podcasts.

References:
  1. Bax CE, Clark AK, Oboite M, Treat JR. A case of disseminated Lyme disease in a child with skin of color. Pediatr Dermatol. Sep 13 2021;doi:10.1111/pde.14770
  2. Fix AD, Pena CA, Strickland GT. Racial differences in reported Lyme disease incidence. Am J Epidemiol. Oct 15 2000;152(8):756-9. doi:10.1093/aje/152.8.756

Category:

Lyme, research, Testing, Treatment

The Ivermectin Story: Live Video Premiere

Live Video Premiere

Don’t miss TONIGHT’s live video premiere of “What is Ivermectin?” Join us at 7pm ET on our YouTube channel to watch the short documentary explaining the medicine’s history and significance. FLCCC President and Co-Chief Medical Officer, Dr. Pierre Kory will introduce the film and then our very own, Betsy Ashton will conduct an interview with the filmmaker, Adrian Urso, after. As a bonus, viewers will be able to interact with our doctors, Dr. Pierre Kory and Dr. Paul Marik in real time.  Join here
 

http://

The Ivermectin Story

 
 
First discovered in 1973, ivermectin won the Nobel Prize in 2015. What makes this drug so extraordinary? Watch the full story during our live premiere on Thursday, Dec. 9 at 7 p.m. ET on our YouTube channel: youtube.com/c/FLCCCAlliance
 
For more:
 
 

Category:

Activism, Treatment, Viruses